Frontline T cell-redirecting therapies in newly diagnosed multiple myeloma: key signals from the 2025 ASH Annual Meeting

Early frontline data presented at the 2025 ASH Annual Meeting suggest that T cell–redirecting strategies, including chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BsAbs), can induce rapid, high rates of minimal residual disease (MRD)-negative responses in newly diagnosed multiple myeloma (NDMM), including transplant-ineligible (TI) and high-risk populations. However, short follow-up, heterogeneous MRD methodologies, and infection risk—particularly with continuous bispecific exposure—underscore that these approaches remain investigational and should be advanced through randomized, MRD-guided fixed-duration trials.